雄激素受体对预测乳腺癌新辅助化疗效果的分析  

Analysis of predictive effect of Androgen receptor on the response to neoadjuvant chemotherapy in breast cancer patients

作　　者：朱久俊 焦得闯 乔江华 王丽娜 马有钊 卢振铎 刘真真 

机构地区：[1]郑州大学附属肿瘤医院河南省肿瘤医院乳腺科,450008

出　　处：《中华医学杂志》2018年第8期601-605,共5页National Medical Journal of China

摘　　要：目的探讨AR在接受新辅助化疗乳腺癌组织中的表达及与临床病理特征的关系，并分析AR在预测病理完全缓解率中的意义。方法回顾收集河南省肿瘤医院2014年3月至2017年6月期间行新辅助化疗患者的病例资料共668例。采用χ2检验比较AR表达与临床病理特征关系，应用Logistic回归分析各个变量与PCR的相关性。结果入组患者均为女性，年龄20～76岁。AR阳性率74.6%，AR表达和HR、HER－2、Ki－67、CK5/6、EGFR及分子分型相关（P〈0.05）。多因素分析：AR、HR及HER－2均为PCR独立预测因素（P〈0.05）。结论AR更多的表达在HR阳性乳腺癌组织中（86.7%），而在TNBC组表达率最低（23.2%）。AR是PCR的独立预测因素。ObjectiveTo explore the expression of androgen receptor （AR） in the tissues as well as its association with the clinicopathological factors of primary breast cancer patients treated with neoadjuvant chemotherapy （NAC）, and analyze the effect of AR in the prediction of pathologic complete response （PCR） rate.MethodA total of 668 breast cancer patients treated with NAC in Henan Cancer Hospital between March 2014 and June 2017 were retrospectively reviewed. The relationship of AR expression and clinicopathological characteristics was calculated using chi square test. Multivariate analysis using binary Logistic regression was used to analyze correlations of different factors with PCR.ResultAll patients were female, with the age of 20-76 years old. AR was detected in 74.6% of tumors, and significantly correlated with hormone receptor （HR）, human epidermalgrowth factor receptor-2 （HER-2）, Ki-67, CK5/6, epidermal growth factor receptor （EGFR） and molecular subtypes （all P〈0.05）. Multivariate analysis showed that AR, HR and HER-2 were independent predictors for PCR （all P〈0.05）.ConclusionsThe expressions of AR were more frequently in HR positive breast cancer tissues （86.7%）, and lowest in triple-negative breast cancer （TNBC） group （23.2%）. AR was independent predictor for PCR.

关 键 词：乳腺肿瘤 新辅助化疗 雄激素受体 病理完全缓解 

分 类 号：R737.9[医药卫生—肿瘤]